Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation

Liver International

Volumn 32, Issue 2, 2012, Pages 179-188

  Saner, Fuat H ^a   Cicinnati, Vito R ^a   Sotiropoulos, Georgios ^a   Beckebaum, Susanne ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Biomarkers; Calcineurin inhibitor sparing regimens; Fluid balance; Immunosuppression; Liver transplantation; Renal perfusion

Indexed keywords

CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYSTATIN C; DACLIZUMAB; DOPAMINE; EVEROLIMUS; FENOLDOPAM; HYDROCORTISONE; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; LOOP DIURETIC AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; NORADRENALIN; ORNIPRESSIN; PLACEBO; RAPAMYCIN; TACROLIMUS; TERLIPRESSIN;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ANEMIA; ARTERY THROMBOSIS; CREATININE BLOOD LEVEL; DIURETIC THERAPY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; FLUID BALANCE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATORENAL SYNDROME; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS ADMINISTRATION; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY INJURY; KIDNEY PERFUSION; LEUKOPENIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; MORTALITY; NEPHROTOXICITY; NONHUMAN; PATIENT CARE; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; REVIEW; SEPTIC SHOCK; STANDARDIZATION; SURGICAL RISK; THROMBOCYTOPENIA; TREATMENT OUTCOME; WOUND DEHISCENCE; WOUND INFECTION;

ACUTE KIDNEY INJURY; BIOLOGICAL MARKERS; CALCINEURIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; POSTOPERATIVE COMPLICATIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84855555406     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02563.x     Document Type: Review

References (102)

1. Barri YM, Sanchez EQ, Jennings LW, et al. Acute kidney injury following liver transplantation: definition and outcome. Liver Transpl 2009; 15: 475-83.
2. Gonwa TA, Mai ML, Melton LB, et al. Renal replacement therapy and orthotopic liver transplantation: the role of continuous veno-venous hemodialysis. Transplantation 2001; 71: 1424-8.
3. Afonso RC, Hidalgo R, Zurstrassen MP, et al. Impact of renal failure on liver transplantation survival. Transplant Proc 2008; 40: 808-10.
4. Ziolkowski J, Paczek L, Senatorski G, et al. Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity. Transplant Proc 2003; 35: 2307-9.
5. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 1934-9.
6. Trawale JM, Paradis V, Rautou PE, et al. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int 2010; 30: 725-32.
7. Saner F, Kavuk I, Lang H, et al. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome. Eur J Med Res 2004; 9: 78-82.
8. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56: 1310-8.
9. Gines P, Guevara M, Arroyo V, Rodes J. Hepatorenal syndrome. Lancet 2003; 362: 1819-27.
10. Guevara M, Gines P, Fernandez-Esparrach G, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35-41.
11. Uriz J, Gines P, Cardenas A, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-8.
12. Martin-Llahi M, Pepin MN, Guevara M, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 1352-9.
13. Sanyal AJ, Boyer T, Garcia-Tsao G, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 2008; 134: 1360-8.
14. Mukhtar A, Salah M, Aboulfetouh F, et al. The use of terlipressin during living donor liver transplantation: effects on systemic and splanchnic hemodynamics and renal function. Crit Care Med 2011; 10: 94-100.
15. Mehta RL, Chertow GM. Acute renal failure definitions and classification: time for change? J Am Soc Nephrol 2003; 14: 2178-87.
16. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-2.
17. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31-8.
18. Kuwabara T, Mori K, Mukoyama M, et al. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int 2009; 75: 285-94.
19. Niemann CU, Walia A, Waldman J, et al. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transpl 2009; 15: 1852-60.
20. Wagener G, Minhaz M, Mattis FA, et al. Urinary neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury after orthotopic liver transplantation. Nephrol Dial Transplant 2011; 26657: 1717-23.
21. Parikh CR, Sandmaier BM, Storb RF, et al. Acute renal failure after nonmyeloablative hematopoietic cell transplantation. J Am Soc Nephrol 2004; 15: 1868-76.
22. Parikh CR, Jani A, Mishra J, et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant 2006; 6: 1639-45.
23. Ichimura T, Bonventre JV, Bailly V, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 1998; 273: 4135-42.
24. Han WK, Wagener G, Zhu Y, Wang S, Lee HT. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 2009; 4: 873-82.
25. Grubb AO. Cystatin C - properties and use as diagnostic marker. Adv Clin Chem 2000; 35: 63-99.
26. Herget-Rosenthal S, Marggraf G, Husing J, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004; 66: 1115-22.
27. Nishiyama A, Majid DS, Walker MIII, Miyatake A, Navar LG. Renal interstitial atp responses to changes in arterial pressure during alterations in tubuloglomerular feedback activity. Hypertension 2001; 37: 753-9.
28. Majid DS, Said KE, Omoro SA, Navar LG. Nitric oxide dependency of arterial pressure-induced changes in renal interstitial hydrostatic pressure in dogs. Circ Res 2001; 88: 347-51.
29. Persson PB, Ehmke H, Kirchheim HR, et al. Autoregulation and non-homeostatic behaviour of renal blood flow in conscious dogs. J Physiol 1993; 462: 261-73.
30. Stocker SD, Sved AF, Stricker EM. Role of renin-angiotensin system in hypotension-evoked thirst: studies with hydralazine. Am J Physiol Regul Integr Comp Physiol 2000; 279: R576-85.
31. Kelleher SP, Robinette JB, Conger JD. Sympathetic nervous system in the loss of autoregulation in acute renal failure. Am J Physiol 1984; 246: F379-86.
32. Biancofiore G, Bindi ML, Romanelli AM, et al. Postoperative intra-abdominal pressure and renal function after liver transplantation. Arch Surg 2003; 138: 703-6.
33. Dalfino L, Tullo L, Donadio I, Malcangi V, Brienza N. Intra-abdominal hypertension and acute renal failure in critically ill patients. Intensive Care Med 2008; 34: 707-13.
34. Mangano CM, Diamondstone LS, Ramsay JG, et al. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med 1998; 128: 194-203.
35. Wang C, Lou TQ, Tang H, et al. Clearance effect of different blood purification techniques on parathyroid hormone in renal function failure patients on maintenance hemodialysis. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2004; 16: 753-5.
36. Cabezuelo JB, Ramirez P, Rios A, et al. Risk factors of acute renal failure after liver transplantation. Kidney Int 2006; 69: 1073-80.
37. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994; 331: 1416-20.
38. Belani KG, Palahniuk RJ. Kidney transplantation. Int Anesthesiol Clin 1991; 29: 17-39.
39. Wilkes NJ, Woolf R, Mutch M, et al. The effects of balanced versus saline-based hetastarch and crystalloid solutions on acid-base and electrolyte status and gastric mucosal perfusion in elderly surgical patients. Anesth Analg 2001; 93: 811-6.
40. O'Malley CM, Frumento RJ, Hardy MA, et al. A randomized, double-blind comparison of lactated Ringer's solution and 0.9% NaCl during renal transplantation. Anesth Analg 2005; 100: 1518-24.
41. Bourgoin A, Leone M, Delmas A, et al. Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function. Crit Care Med 2005; 33: 780-6.
42. Osthaus WA, Huber D, Baumker C, et al. Plasma volume replacement with HES 130/0.42 obviates negative side effects of pneumoperitoneum in piglets. Paediatr Anaesth 2008; 18: 922-8.
43. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125-39.
44. Mukhtar A, Aboulfetouh F, Obayah G, et al. The safety of modern hydroxyethyl starch in living donor liver transplantation: a comparison with human albumin. Anesth Analg 2009; 109: 924-30.
45. Payen D, de Pont AC, Sakr Y, et al. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care 2008; 12: R74-80.
46. Bouchard J, Soroko SB, Chertow GM, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int 2009; 76: 422-7.
47. Foland JA, Fortenberry JD, Warshaw BL, et al. Fluid overload before continuous hemofiltration and survival in critically ill children: a retrospective analysis. Crit Care Med 2004; 32: 1771-6.
48. Gillespie RS, Seidel K, Symons JM. Effect of fluid overload and dose of replacement fluid on survival in hemofiltration. Pediatr Nephrol 2004; 19: 1394-9.
49. Goldstein SL. Hemodialysis in the pediatric patient: state of the art. Adv Ren Replace Ther 2001; 8: 173-9.
50. Hayes GR, Williams A, Costello CE, Enns CA, Lucas JJ. The critical glycosylation site of human transferrin receptor contains a high-mannose oligosaccharide. Glycobiology 1995; 5: 227-32.
51. Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ 2006; 333: 420.
52. Kellum JA. Diuretics in acute renal failure: protective or deleterious. Blood Purif 1997; 15: 319-22.
53. McDonald RH Jr, Goldberg LI, McNay JL, Tuttle EP Jr Effect of dopamine in man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. J Clin Invest 1964; 43: 1116-24.
54. Kellum JA, Decker M. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001; 29: 1526-31.
55. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356: 2139-43.
56. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362: 779-89.
57. Halpenny M, Rushe C, Breen P, et al. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. Eur J Anaesthesiol 2002; 19: 32-9.
58. Stone GW, McCullough PA, Tumlin JA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290: 2284-91.
59. Morelli A, Ricci Z, Bellomo R, et al. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial. Crit Care Med 2005; 33: 2451-6.
60. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-40.
61. Sharma P, Welch K, Eikstadt R, et al. Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl 2009; 15: 1142-8.
62. Gonwa TA, McBride MA, Anderson K, et al. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 2006; 6: 2651-9.
63. Bahirwani R, Reddy KR. Outcomes after liver transplantation: chronic kidney disease. Liver Transpl 2009; 15(Suppl. 2): S70-4.
64. Farkas SA, Schnitzbauer AA, Kirchner G, et al. Calcineurin inhibitor minimization protocols in liver transplantation. Transpl Int 2009; 22: 49-60.
65. Kornberg A, Kupper B, Hommann M, Scheele J. Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction. Int Immunopharmacol 2005; 5: 141-6.
66. Cicinnati VR, Yu Z, Klein CG, et al. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients - assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther 2007; 26: 1195-208.
67. Biselli M, Vitale G, Gramenzi A, et al. Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant. Clin Transplant 2009; 23: 191-8.
68. Nishibayashi S, Hattori K, Hirano T, et al. Functional and structural changes in end-stage kidney disease due to glomerulonephritis induced by the recombinant alpha3(IV)NC1 domain. Exp Anim 2010; 59: 157-70.
69. Tapia E, Franco M, Sanchez-Lozada LG, et al. Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension. Kidney Int 2003; 63: 994-1002.
70. Allison AC, Eugui EM. Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 2005; 80: S181-90.
71. Shipkova M, Armstrong VW, Oellerich M, Wieland E. Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 2005; 1: 505-26.
72. Brunet M, Cirera I, Martorell J, et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation 2006; 81: 541-6.
73. Robaeys G, Cassiman D, Verslype C, et al. Successful conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic) in liver transplant patients with gastrointestinal side effects. Transplant Proc 2009; 41: 610-3.
74. Pietruck F, bbud-Filho M, Vathsala A, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international, multicenter studies. Transplant Proc 2007; 39: 103-8.
75. Nashan B, Ivens K, Suwelack B, Arns W, Abbud FM. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the myfortic prospective multicenter study. Transplant Proc 2004; 36: 521S-3S.
76. Budde K, Curtis J, Knoll G, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4: 237-43.
77. Cooper M, Deering KL, Slakey DP, et al. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients. Transplantation 2009; 88: 514-20.
78. Pageaux GP, Rostaing L, Calmus Y, et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl 2006; 12: 1755-60.
79. Kornberg A, Kupper B, Thrum K, et al. Sustained Renal Response to Mycophenolate Mofetil and CNI Taper Promotes Survival in Liver Transplant Patients with CNI-Related Renal Dysfunction. Dig Dis Sci 2010; 56: 244-51.
80. Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009; 9: 327-36.
81. Yoshida EM, Marotta PJ, Greig PD, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005; 11: 1064-72.
82. Bajjoka I, Hsaiky L, Brown K, Abouljoud M. Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors. Liver Transpl 2008; 14: 66-72.
83. Soliman T, Hetz H, Burghuber C, et al. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl 2007; 13: 1039-44.
84. Dharancy S, Iannelli A, Hulin A, et al. Mycophenolate mofetil monotherapy for severe side effects of calcineurin inhibitors following liver transplantation. Am J Transplant 2009; 9: 610-3.
85. Moreno Planas JM, Cuervas-Mons MV, Rubio GE, et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant 2004; 4: 1650-5.
86. Fairbanks KD, Thuluvath PJ. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl 2004; 10: 1189-94.
87. Ko HH, Greanya E, Lee TK, et al. Mycophenolate mofetil in liver transplant patients with calcineurin-inhibitor-induced renal impairment. Ann Hepatol 2008; 7: 376-80.
88. Manrique A, Jimenez C, Ortega P, et al. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis. Transplant Proc 2008; 40: 2962-4.
89. Schlitt HJ, Barkmann A, Boker KH, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 587-91.
90. Wood KJ, Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199-210.
91. Zeiser R, Nguyen VH, Beilhack A, et al. Inhibition of CD4+CD25+regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108: 390-9.
92. Demirkiran A, Sewgobind VD, van der WJ, et al. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+regulatory T cells. Transplantation 2009; 87: 1062-8.
93. DuBay D, Smith RJ, Qiu KG, et al. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl 2008; 14: 651-9.
94. Harper SJ, Gelson W, Harper IG, Alexander GJ, Gibbs P. Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: A single-center experience. Transplantation 2010; 91: 128-32.
95. Watson CJ, Gimson AE, Alexander GJ, et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2007; 13: 1694-702.
96. Shenoy S, Hardinger KL, Crippin J, et al. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. Transplantation 2007; 83: 1389-92.
97. Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 2010; 10: 2252-62.
98. Castroagudin JF, Molina E, Romero R, et al. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl 2009; 15: 1792-7.
99. Schnitzbauer AA, Scherer MN, Rochon J, et al. Study protocol: a pilot study to determine the safety and efficacy of induction-therapy, de novo MPA and delayed mTOR-inhibition in liver transplant recipients with impaired renal function. PATRON-study. BMC Nephrol 2010; 11: 24-30.
100. Teperman L, Sher L, Marotta P, et al. Efficacy of mycophenolate mofetil/sirolimus maintenance therapy after CNI withdrawal in liver transplant recipients: 1-year outcomes of the spare-the-nephron (STN) trial. Am J Transplant 2011; 9: 229-30.
101. Cattaneo D, Merlini S, Zenoni S, et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant 2005; 5: 2937-44.
102. Boillot O, Seket B, Dumortier J, et al. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. Liver Transpl 2009; 15: 1426-34.